Imaging Synaptic Changes Over Time in Parkinson's Disease
Follows people with Parkinson's disease and healthy controls using brain scans and cognitive testing.
Plain-language title generated from the registry record
Registry title: Long-term Longitudinal Imaging of Presynaptic Terminals in PD
Key facts
- Where
- Leuven, BelgiumSee the site
Where in Belgium
- UZ LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitaire Ziekenhuizen KU Leuven
- Trial code
- NCT06875765
- Record updated
- 29 July 2025
- Original description
AIM: To investigate whether SV2A loss spreads from brainstem to cerebral cortex with progression of Parkinson's disease (PD) and to determine whether longitudinal cortical SV2A loss correlates with cognitive decline in PD.Read full original descriptionShow less
Longitudinal Measurement of Synaptic Loss and Cognitive Decline in the Long-term Course of Parkinson's Disease
AIM: To investigate whether SV2A loss spreads from brainstem to cerebral cortex with progression of Parkinson's disease (PD) and to determine whether longitudinal cortical SV2A loss correlates with cognitive decline in PD.
STUDY DESIGN: The investigators will re-invite participants (both patients with PD and healthy controls) of a previous longitudinal study (NCT04243304, S61477) to undergo evaluation approximately 7 years after the initial baseline study visit (i.e. on average 10 years since the first motor symptoms). All participants will undergo clinical assessment of motor and non-motor symptoms (including cognitive testing), as well as 11C-UCB-J PET-CT (targeting synaptic density marker SV2A), 18F-FE-PE2I PET-CT (targeting DAT) and brain MRI.
Inclusion: Participation in study S61477 (NCT04243304).
Exclusion: Previous participation in other research studies involving ionizing radiation with > 1 mSv over past 12 months; Neuropsychiatric diseases (unrelated to PD for PD patients); Major internal medical diseases; History of alcohol or drug abuse; Relevant abnormalities on MR brain; Contraindications for MR; Pregnancy or breastfeeding.